PRPO - Precipio, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.42
+0.01 (+2.04%)
At close: 4:00PM EDT

0.40 -0.02 (-4.29%)
After hours: 4:15PM EDT

Stock chart is not supported by your current browser
Previous Close0.41
Open0.43
Bid0.40 x 800
Ask0.44 x 3000
Day's Range0.40 - 0.43
52 Week Range0.32 - 2.65
Volume171,666
Avg. Volume1,065,485
Market Cap9.725M
Beta2.01
PE Ratio (TTM)N/A
EPS (TTM)-2.57
Earnings DateNov 19, 2018 - Nov 23, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Trade prices are not sourced from all markets
  • GlobeNewswire10 hours ago

    Precipio Enters into Exchange Agreement to Restructure Remaining Legacy Accounts Payable for approximately 20% of Original ~$5M

    Specialty cancer diagnostics Company Precipio, Inc. (NASDAQ: PRPO), announces the restructuring of its remaining legacy, pre-merger accounts payable liabilities, pursuant to an exchange which is made in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933. The payments made to note holders are equal to approximately 20% of the original $5.3 million, and are funded through a convertible note with existing investors. Important benefits of this transaction include the postponement of $82,000 in monthly debt service for a period of 12 months, and the ability during that time to convert the notes at a 65% premium to market, effectively reducing by almost half the dilution that would have otherwise resulted from raising capital necessary to satisfy these obligations.

  • GlobeNewswireyesterday

    Precipio Expands ICE-COLD PCR™ Lung Cancer Mutation Detection Offering

    The kit provides physicians the ability to use a liquid biopsy to identify patients eligible for Tyrosine Kinase Inhibitor (TKI) therapies through analysis of tumor DNA for these critical EGFR mutations. The presence of such mutations indicates the patient’s eligibility for various targeted therapies including TKI. This kit complements Precipio’s previously-launched TKI-resistance detection kit, providing the clinician with a full suite of sequential lung-cancer diagnostic tools critical to determining patient treatment.

  • ACCESSWIRElast month

    Precipio, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 23, 2018 / Precipio, Inc. (NASDAQ: PRPO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 23, 2018 at 9:00 AM Eastern Time. To ...

  • GlobeNewswirelast month

    Precipio Reminds Investors of Conference Call with Management for Corporate Update and Second Quarter Results

    Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), wishes to remind investors and shareholders of its previously announced shareholder conference call scheduled for tomorrow, Thursday August 23, 2018 at 9:00 am EDT, where management will provide a strategic business update and address questions submitted in advance via email. All callers should ask for the Precipio Inc., conference call. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard’s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.

  • GlobeNewswirelast month

    Precipio Announces Second Quarter 2018 Financial Results and Provides Corporate Update

    Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has filed its form 10-Q and released it’s financial results for the second quarter ended June 30, 2018. All callers should ask for the Precipio Inc., conference call. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard’s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.

  • GlobeNewswirelast month

    Precipio Appoints New Board Member to Replace Departing Director

    Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the appointment of veteran life sciences venture capitalist and executive Kathleen LaPorte to its board of directors as an independent member. Ms. LaPorte will replace Dr. Michael Allen Luther who served on Transgenomic’s board since 2014 and remained as member of Precipio’s board since the merger in June 2017.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Texas Instruments and Precipio

    NEW YORK, NY / ACCESSWIRE / July 19, 2018 / Texas Instruments Incorporated closed down modestly on Wednesday. The company's CEO Brian Crutcher recently resigned for violating conduct and in his place, former CEO Rich Templeton has taken his position. Shares of Precipio saw big gains after announcing preliminary second quarter results.

  • GlobeNewswire2 months ago

    Precipio Announces 213% Year-over-Year Revenue Growth in Preliminary Q2-2018 Results

    Specialty cancer diagnostics company Precipio, Inc. (PRPO), today announced preliminary second quarter results representing continued triple digit YoY growth. Quarter over quarter sequential growth was 14% which, at a compounded run rate of circa 70% annually currently represents early stage growth generated from pathology services. In Q4-2017 and in Q1-2018, YoY revenue growth was 199% and 187% respectively, showing continued triple-digit YoY growth.

  • GlobeNewswire3 months ago

    Precipio and Nucleai Partner to Develop Artificial Intelligence-Powered Hemepath Solution

    Specialty diagnostics company Precipio, Inc. (PRPO), announced today an agreement with Israel-based artificial intelligence pathology platform company Nucleai who specializes in applying Machine Learning and Machine Vision algorithms to pathology domain. Nucleai’s experienced team has adapted artificial intelligence technology previously used for satellite image analysis to the detection of cancer using biopsy image analysis to distinguish between abnormal, potentially malignant cells and normal cells.

  • ACCESSWIRE3 months ago

    Initiating Free Research Reports on Quest Diagnostics and Three Other Medical Research Equities

    Stock Research Monitor: PKI, PRAH, and PRPO LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on DGX sign up now at www.wallstequities.com/registration . On Monday, benchmark US ...

  • Who Owns Most Of Precipio Inc (NASDAQ:PRPO)?
    Simply Wall St.4 months ago

    Who Owns Most Of Precipio Inc (NASDAQ:PRPO)?

    In this analysis, my focus will be on developing a perspective on Precipio Inc’s (NASDAQ:PRPO) latest ownership structure, a less discussed, but important factor. A company’s ownership structure is oftenRead More...

  • ACCESSWIRE4 months ago

    Complimentary Technical Snapshots on Thermo Fisher Scientific and Three More Medical Research Stocks

    Ahead of today's trading session, WallStEquities.com scans four Medical Laboratories and Research stocks, particularly: PerkinElmer Inc. (NYSE: PKI), Precipio Inc. (NASDAQ: PRPO), Syneos Health Inc. (NASDAQ: SYNH), and Thermo Fisher Scientific Inc. (NYSE: TMO). Medical laboratories are independent, commercial enterprises that provide information to the health care professionals about the severity, onset, and reason of patients' physical ailments.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Precipio and Teva Pharmaceutical

    NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Shares of Precipio and Teva were gaining full speed on Monday. Precipio shares exploded after the company announced a substantial preliminary unaudited first ...